Financial PerformanceFor 2Q25, the company reported no revenues, in-line with consensus estimates, and a net loss of $0.30 per diluted share.
Risks To Buy RatingRisks to the Buy rating include financial, clinical, manufacturing, legal and intellectual property, regulatory, competition, commercial, and pipeline challenges.